AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Medistim

AGM Information Apr 25, 2018

3662_rns_2018-04-25_afb3320a-28ab-42e5-b471-4393ebd78a5f.pdf

AGM Information

Open in Viewer

Opens in native device viewer

MINUTES FROM THE GENERAL MEETING IN MEDISTIM ASA

Medistim ASA held its ordinary general meeting Wednesday the 25th of April 2018 at 10.00. The meeting was held at the company offices in Økernveien 94 in Oslo. Attachment 1 gives an overview of the shareholders that were represented. 57.41 % of the shareholders were represented were 30.23 % were represented by proxy.

Chairman of the Board of Director's Øyvin Anders Brøymer opened the meeting.

The agenda for the meeting was as follows:

1. Approval of notice and power of attorney

There were no comments to the notice, the agenda or proxies and these were approved. 1,270,746 votes of total 10,527,959 votes abstained to vote on this point. The meeting was pronounced lawfully called and assembled.

2. Appointment of person to chair the meeting, to sign the protocol, to co-sign the protocol and protocol secretary

Øyvin Anders Brøymer was chosen to chair the meeting. Rigmor Blix and Kari Krogstad were chosen to sign the minutes together with Øyvin Brøymer. Thomas Jakobsen was chosen as secretary for the meeting. All elections were unanimously chosen.

3. Approval of annual report for 2017

The Chairman of the meeting went through the annual report for 2017. The General Assembly took note of this and there were no comments to the report.

4. Approval of the income statement and balance sheet for 2017

The income statement and balance sheet for 2016 was presented for the holding company and the group to the general meeting by the chairman of the meeting. The general meeting took notice of the presentation and there were no comments to the presentation. The income statement for 2017 and balance sheet for 2017 for the holding company and the group were approved.

5. Allocation of profit for 2017

The profit for 2017 was TNOK 38,420 for the holding company. The Board of Directors suggested a dividend to the shareholders of NOK 2.00 per share, total TNOK 36,358 and that TNOK 2,062 is transferred to other equity. The company has 158,500 Medistim shares and does not pay dividend on own shares. Shareholders registered in VPS by the end of the 25th of April 2018 will have the right to the dividend. The Board of director's suggestion was approved unanimously by the general assembly. The Medistim shares will be traded as ex dividend NOK 2.00 as of the 26th of April.

6. The Board of Director's declaration on salary and other remuneration to the management

The Chairman gave an orientation to the general meeting of the principals used to set salary and remuneration to the management and key personnel. The declaration is also described in the annual report. The general meeting took notice of the orientation. Of a total of 10,527,959 votes, 8,933,672 of the votes approved the principles, while 1,594,287 of the votes where against the principles. As a conclusion the General Meeting approved the principals for salary and remuneration to management and key personnel.

7. Approval of fee to the auditor

Fee to the auditor was in total TNOK 459 where TNOK 402 was for the audit and TNOK 57 was for other services. The fee to the auditor was approved by the general meeting.

8. Election of board members. Three of the board members are on election

Three of the board members, deputy chairman Bjørn M. Wiggen and board members Tove Raanes and Lars Rønn, were on election for a new term of two years. The nomination committee recommends that all candidates are elected for a new term of two years. The candidates were unanimously elected, Bjørn M. Wiggen as deputy chairman and Tove Raanes and Lars Rønn as board members for a two year term until ordinary general meeting in 2020.

9. Approval of fee to the Board of Director's

The fee to the Board of Director's in 2017 was NOK 375.000 to the Chairman. Fee to the board members was NOK 210.000 to 4 members. Total fee for 2017 was NOK 1,215,000. The fee to the Board of Director's was approved by the general meeting.

10. Election of members to the nomination committee

The leader of the nomination committee, Johan Skjøldberg, was on election. Johan Skjøldberg was not willing to take a new term. It was suggested that nomination committee member, Bjørn Henrik Rasmussen, was elected as leader for the nomination committee for one term until the ordinary general meeting I 2019. Further, it was suggested that Kristin Eriksen was elected as member of the nomination committee for two terms until the ordinary general meeting in 2020. Bjørn Henrik Rasmssen represents Medistims fourth largest shareholder and Kristin Eriksen represents Medistims second largest shareholder. Both candidates was willing to take the suggested term. Bjørn Henrik Rasmussen was elected as leader of the nomination committee until the ordinary general meeting in 2019. Kristin Eriksen was elected as member of the nomination committee until the ordinary general meeting in 2020.

11. Approval of fee to the nomination committee

It was suggested to the General Meeting that the leader of the Nomination Committee was compensated with 20 TNOK and that the members were compensated with 15 TNOK. Total purposed fee to the Nomination Committee was 50 TNOK. Of a total of 10,527,959 votes, 9,152,713 of the votes approved the fee to the nomination committee, while 1,375,246 of the votes where against the fee to the nomination committee. The fee to the nomination committee was approved by the general meeting.

12. Approval of the Board of Director's suggestion to the general meeting to renew the Board of Director's authorisation to increase share capital.

The general meeting gave the Board of director's approval to increase share capital on the following terms and conditions:

  • A. The Board of Director's is authorised to increase share capital up to NOK 458,433.25 by issuing up to 1,833,733 new shares at par value of NOK 0.25. The share price and other terms when issuing new shares are set by the board of directors. The board of directors can increase the share capital once or in several different occasions.
  • B. In case of a change in par value of the share as a result of a split, fond emission or something similar, is the authorisation adjusted accordingly with the number of shares that can be issued. The share price and other terms are adjusted according to generally known principles for such adjustments, but always within the regulations in the Public Limited Companies Act.
  • C. The authorisation shall also include capital increase against other assets than cash deposits.
  • D. The shareholders preferential rights to subscribe shares can be set aside by the board according to the Public Limited Companies Act § 10-4.
  • E. The authorisation shall include a decision including a fusion according to Public Limited Companies Act § 13-5.
  • F. The authorisation is valid until the next ordinary general meeting.

The general meeting approved the Board of Director's authorisation to increase share capital unanimously according to the above terms and conditions.

The general meetings resolution will be registered in the Brønnøysund register centre and must be registered before the Board of Directors can use the authorisation.

13. Approval of authorisation to purchase own shares

The general meeting gave the board of directors renewed power of attorney to purchase own shares on the following terms and conditions:

  • A. The authorisation is valid until the next general meeting.
  • B. The company can purchase shares at par value up to NOK 458,433.25, which are 1,833,733 shares at today's par value.
  • C. The highest price per share shall maximum be NOK 150.00 per share.
  • D. The lowest price per share shall minimum be NOK 0.25 per share.

E. The Board of Director's can freely decide how to purchase the shares as long as the principle for equal treatment is followed.

The general meeting approved the power of attorney to purchase own shares unanimously according to above terms and conditions.

The general meeting resolution must be registered in the Brønnøysund register centre before the board can use the authorisation.

* * *

There were no other issues on the agenda. The meeting was ended and the minutes signed.

Oslo 25. April 2018

Sign. Sign. Sign.

_____________ _________________ ___________________

Rigmor Blix Øyvin A. Brøymer Kari Eian Krogstad

Results of the voting and participation at the General meeting in Medistim ASA the 26th of April 2017 Enclosure to General Meeting protocol

Res
ults
of
the
n th
e G
ral m
ing
in M
edis
tim
ASA
vot
eet
es o
ene
In fa
vou
r
Aga
inst
Abs
tain
1. A
l of
the
ice,
istra
tion
of
sha
reh
olde
ted
by
not
ppr
ova
reg
rs o
r pe
rson
s re
pre
sen
pro
xy.
9 25
7 21
3
1 2
70 7
46
2. A
intm
of
cha
ir th
ing,
sign
the
ol, t
‐sig
n th
col
and
ol s
ed i
n th
al m
ing.
ent
to
eet
to
toc
oto
toc
tary
eet
ppo
per
son
e m
pro
o co
e pr
pro
ecre
pro
pos
e ge
ner
959
10
527
3. A
l of
ual
for
201
6.
ort
ppr
ova
ann
rep
10 5
27 9
59
4. A
l of
fit a
nd l
and
ba
lanc
e sh
201
6.
eet
ppr
ova
pro
oss
10 5
27 9
59
5. A
l of
the
dis
trib
utio
n of
the
fit f
he y
or t
ppr
ova
pro
ear
10 5
27 9
59
6. T
he B
d of
Dir
r's d
ecla
rati
lary
and
oth
rati
o th
ecto
on t
ent
oar
on o
n sa
er r
em
une
e m
ana
gem
72
8 9
33 6
87
94 2
1 5
l of
fee
he a
udit
or f
or 2
016
7. A
to t
ppr
ova
10 5
27 9
59
8. E
lect
ion
of b
d m
ber
of t
he b
d m
ber
ele
ctio
his
is a
rdin
The
min
atio
itte
e's
tion
s. T
n. T
g to
No
n Co
oar
em
wo
oar
em
s ar
e on
cco
mm
sug
ges
959
10
527
the
ard
. Th
is is
ord
ing
he N
inat
ion
mit
's su
stio
9. F
to
Bo
to t
Com
tee
ees
acc
om
gge
n.
10 5
27 9
59
The
mbe
he N
inat
ion
mit
. Th
is is
ord
ing
he N
inat
ion
mit
's su
stio
10.
rs t
Com
tee
to t
Com
tee
me
om
acc
om
gge
n.
959
10
527
sati
o th
inat
ion
mit
. Th
is is
ord
ing
he N
inat
ion
mit
's su
stio
11.
Com
on t
e N
Com
tee
to t
Com
tee
pen
om
acc
om
gge
n.
13
9 1
52 7
46
1 3
75 2
l of
the
ard
of
r's s
o th
al m
he B
d of
r's a
uth
e sh
ital.
12.
App
Bo
Dire
cto
esti
on t
eet
ing
to r
w t
Dir
ecto
oriz
atio
n to
inc
rova
ugg
e ge
ner
ene
oar
reas
are
cap
959
10
527
l of
the
ard
of
r's s
the
of
rcha
sha
13.
App
Bo
Dire
cto
esti
on t
atto
y to
rova
ugg
o re
new
po
wer
rne
pu
se o
wn
res
959
10
527

Shareholders at the General Meeting:

Asb
jørn
Bu
ane
ss
494
936
Inte
de s
hipp
ing
rtra
4 00
3 50
0
Kar
i Kr
tad
ogs
112
500
Rigm
lix
or B
140
000
Tho
Jak
obs
mas
en
75 0
00
dist
im A
SA's
e ak
sjer
Me
egn
158
500
n th
gh p
Part
icip
atio
rou
roxy
Pro
xy t
o
Pre
vot
e
A/S
DAN
SKE
BA
NK
an Ø
Cha
285
03
1
irm
yvin
Brø
yme
r
In f
n al
l ite
avo
ur o
ms
DAN
SKE
INV
EST
NO
RGE
an Ø
Cha
250
000
irm
yvin
Brø
yme
r
In f
n al
l ite
avo
ur o
ms
SW
EDB
ANK
RO
BUR
NY
TE
an Ø
Cha
1 37
5 24
6
irm
yvin
Brø
yme
r
In f
n al
l ite
mbe
d 11
6 an
ept
avo
ur o
ms
exc
nu
r
GRA
NDE
UR
PEA
K IN
TER
NAT
ION
AL
Cha
an Ø
420
559
irm
yvin
Brø
yme
r
Abs
tain
ite
m 1
GRA
NDE
UR
PEA
K G
LOB
AL O
PPO
RTU
NIT
IES
FUN
D
Cha
an Ø
152
700
irm
yvin
Brø
yme
r
Abs
tain
ite
m 1
GRA
NDE
UR
PEA
K G
LOB
AL R
EAC
H F
UND
Cha
an Ø
75 1
50
irm
yvin
Brø
yme
r
Abs
tain
ite
m 1
GRA
NDE
UR
PEA
K G
LOB
AL O
PPO
RTU
NIT
IES
L.P
an Ø
47 5
00
Cha
irm
yvin
Brø
yme
r
Abs
tain
ite
m 1
FIN
INV
TST
GR
AND
PEA
K G
LOB
MI
CRO
an Ø
25 8
62
Cha
irm
yvin
Brø
yme
r
Abs
tain
ite
m 1
NN
PAR
APL
UFO
NDS
1 N
an Ø
205
624
Cha
irm
yvin
Brø
yme
r
In f
n al
l ite
ber
6 an
d ab
stai
ite
ept
avo
ur o
ms
exc
nu
m
n on
SEB
EU
ROP
EAN
EQ
UIT
Y SM
ALL
CA
P
an Ø
500
000
Cha
irm
yvin
Brø
yme
r
In f
n al
l ite
avo
ur o
ms
DAN
SKE
INV
EST
SIC
RV
EUR
OPE
SM
ALL
an Ø
329
934
Cha
irm
yvin
Brø
yme
r
Abs
tain
ite
m 1
OD
DO
an Ø
13 4
17
Cha
irm
yvin
Brø
yme
r
In f
n al
l ite
ber
6 an
d 11
ept
avo
ur o
ms
exc
n
um
SAL
VES
EN &
TH
AM
S IN
V
an Ø
1 86
2 50
0
Cha
irm
yvin
Brø
yme
r
In f
n al
l ite
avo
ur o
ms
In %
of
l nu
mbe
r of
sha
tota
res
Tot
al n
ber
of s
har
eho
lder
ted
he m
ing
at t
eet
um
s re
pre
sen
10 5
27 9
59
57,
41 %
al n
ber
of s
har
eho
lder
ted
he m
ing
Tot
at t
eet
um
s re
pre
sen
10 5
27 9
59
41 %
57,
al n
ber
of s
har
eho
lder
ted
he m
ing
thro
ugh
Tot
at t
eet
um
s re
pre
sen
pro
xy
5 54
3 52
3
23 %
30,
al n
ber
of s
har
and
Tot
utst
ing
um
es o
18 3
37 3
36

Talk to a Data Expert

Have a question? We'll get back to you promptly.